StreetAlpha.app
Home › Stocks › VRDN

Viridian Therapeutics, Inc. (VRDN)

Healthcare
$30.06
▲ +0.87%
LAST CLOSE · NOV 17

Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare diseases, with a focus on thyroid eye disease. It last closed at $30.06 on Nov 17, up 0.87% on the day. The average 12-month price target from 8 analysts is $41.13 (+36.8% from the last close), with a high of $54.00 and a low of $33.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $4.8M, the largest $3.0M.

AI Auto Pilots
Is VRDN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$26.3M
−62.8% vs a year ago
Net income
−$453.6M
−1724.1% margin
Free cash flow
−$343.4M
−1305.4% margin
Operating margin
−1781.4%
−$468.7M operating income
Valuation
Market cap
$3.4B
113.6M shares
P/E
–
Price to sales
129.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$172.9M
At Sep 30
Debt
$242.5M
At Sep 30
Shareholder equity
$580.7M
Shares outstanding
113.6M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0M$3.0MFY2021FY2022: $1.8M$1.8MFY2022FY2023: $314K$314KFY2023FY2024: $302K$302KFY2024FY2025: $70.8M$70.8MFY2025

From VRDN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
8 Buy0 Hold0 Sell
Each firm's latest rating on VRDN in the past 90 days
Average 12-month target
$41.13
▲ 36.8% upside

Based on 8 analysts who set a price target on VRDN in the past 90 days. The average target is $41.13, with a high of $54.00 and a low of $33.00, compared with the last close of $30.06.

Low $33.00Avg $41.13High $54.00
Blue marker: last close $30.06
Highest target$54.00
Average target$41.13
Lowest target$33.00
Latest rating changes
Wells FargoTarget raised
Nov 10Buy$34 → $39
Leerink PartnersMaintained
Nov 5Buy$54
RBC CapitalTarget raised
Nov 5Buy$38 → $41
Truist SecuritiesTarget raised
Nov 5Buy$39 → $42
Wells FargoTarget raised
Nov 5Buy$31 → $34
DateFirmActionRatingPrice target
Nov 10Wells FargoTarget raisedBuy$34 → $39
Nov 5Leerink PartnersMaintainedBuy$54
Nov 5RBC CapitalTarget raisedBuy$38 → $41
Nov 5Truist SecuritiesTarget raisedBuy$39 → $42
Nov 5Wells FargoTarget raisedBuy$31 → $34
Loading…

Technical Analysis

VRDN · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 10% above its 20 day and 23% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 70), overbought. The nearest support is the Pivot at $29.82, and the nearest resistance the Pivot R1 at $30.36.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 4.4%/day
Key levels
$34.2952 week high+14.1%
$31.63Swing high (Nov 11)+5.2%
$30.36Pivot R1+1.0%
$30.06Last close
$29.82Pivot−0.8%
$29.52Pivot S1−1.8%
$26.9720 day average−10.3%
$23.0250 day average−23.4%
$22.10100 day average−26.5%
$21.62Swing low (Aug 14)−28.1%
$21.52200 day average−28.4%
$13.1852 week low−56.2%
Indicators
RSI (14)70.14Overbought above 70Overbought
MACD2.44Above its signal lineBullish
Stochastic82.5Near the top of its rangeOverbought
ADX (14)51.6Strong uptrend
Williams %R-20.5Oversold below −80, overbought above −20Neutral
CCI (20)67.4Oversold below −100, overbought above 100Neutral
Rate of change+19.5%Change over 10 sessionsBullish
ATR (14)$1.32Typical daily range, 4.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for VRDN

What happened before

See how VRDN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VRDN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VRDN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VRDN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$4.8M
Largest print
$3.0M
Loading…

VRDN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲124 buying vs 87 selling
  • ▲Held by funds +1.1 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding235217+8.3%
In funds' top 1097+28.6%
Held by funds120.9%119.8%+1.1 pts
New / increased42 / 8246 / 95−12.1%
Reduced / sold out63 / 2449 / 55−16.3%
Put/call ratio79.730.09+85060.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VRDN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRDN is in one of them and how their past VRDN trades turned out.

VRDN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VRDN in an article yet. Here's the latest on the wider market.

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts. It develops medicines for serious and rare diseases, with its main focus on thyroid eye disease, a rare autoimmune condition that affects the eyes. Its pipeline includes antibody treatments that target the IGF-1R pathway and engineered FcRn inhibitors being studied for several autoimmune disorders. The company is preparing to sell its medicines to patients, physicians and insurers if they are approved.

Headquarters
Waltham, MA